12-2439-42
antibody from Invitrogen Antibodies
Targeting: ABCB1
ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1
Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 12-2439-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD243 (ABCB1) Monoclonal Antibody (UIC2), PE, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: This monoclonal antibody reacts with human Multidrug Resistant (MDR)-1, which is also known as P-glycoprotein (Pgp) and CD243. A 170-kDa transmembrane protein, MDR-1 is an ATP-dependent efflux pump for lipophilic compounds, including anti-cancer drugs. Expression of MDR-1 has been shown to correlate with multidrug resistance. In fact, tumor resistance to chemotherapy has been linked to MDR-1 expression in many cancers. MDR-1 is expressed in a variety of tissues, including the brain, kidney, liver, pancreas, and testes. Within the immune system, this molecule can be found on normal T, B, and natural killer cells, but not on monocytes.
- Conjugate
- Yellow dye
- Antibody clone number
- UIC2
- Concentration
- 5 µL/Test
Submitted references Optimized Stem Cell Detection Using the DyeCycle-Triggered Side Population Phenotype.
Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors.
Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy.
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
Identification of a candidate proteomic signature to discriminate multipotent and non-multipotent stromal cells.
Boesch M, Wolf D, Sopper S
Stem cells international 2016;2016:1652389
Stem cells international 2016;2016:1652389
Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors.
Cannon CM, Pozniak J, Scott MC, Ito D, Gorden BH, Graef AJ, Modiano JF
Veterinary and comparative oncology 2015 Mar;13(1):48-59
Veterinary and comparative oncology 2015 Mar;13(1):48-59
Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy.
Das SG, Hermanson DL, Bleeker N, Lowman X, Li Y, Kelekar A, Xing C
ACS chemical biology 2013 Feb 15;8(2):327-35
ACS chemical biology 2013 Feb 15;8(2):327-35
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
Gojo I, Tan M, Fang HB, Sadowska M, Lapidus R, Baer MR, Carrier F, Beumer JH, Anyang BN, Srivastava RK, Espinoza-Delgado I, Ross DD
Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Apr 1;19(7):1838-51
Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Apr 1;19(7):1838-51
Identification of a candidate proteomic signature to discriminate multipotent and non-multipotent stromal cells.
Rosu-Myles M, She YM, Fair J, Muradia G, Mehic J, Menendez P, Prasad SS, Cyr TD
PloS one 2012;7(6):e38954
PloS one 2012;7(6):e38954
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of the 8226/S (left) and 8226 DOX40 (right) cell lines with Mouse IgG2a K Isotype Control PE (Product # 12-4724-81) (blue histogram) or Anti-Human CD243 (ABCB1) PE (purple histogram). Total viable cells were used for analysis.
- Conjugate
- Yellow dye
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Characterization of DCV-SP cells using pharmacological inhibition and antibody-based costaining of SP-conferring drug transporters. A2780V cells containing ABCB1-positive SP (a) and parental A2780 cells harbouring an ABCG2-positive SP (b) were stained with 10 mu M DCV (10 6 cells/mL) and subjected to a set of control experiments. Specifically, the samples were inhibited using 50 mu M verapamil (blocking several drug transporters) or 20 mu M fumitremorgin C (blocking ABCG2 specifically) or, where indicated, both. In addition, noninhibited and inhibited cells were costained for the drug transporters ABCB1 and ABCG2 using respective monoclonal antibodies. This multimodal approach helped us to better define particularly A2780V cells, whose SP contains a major population of ABCB1-positive cells (~8-10%) and a minor population of ABCG2-expressing cells (~0.1%). Note that, at least in our model systems, verapamil does not inhibit the activity of ABCG2.
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 8 SP detection using the second-generation DyeCycle dyes DCG and DCO. A2780V cells harbouring an ABCB1-positive SP (a) and parental A2780 cells containing an ABCG2-positive SP (b) were stained with 500 nM of either DCG or DCO (10 6 cells/mL) and analysed by flow cytometry using the indicated emission filters (DCO data accentuated by dotted lines). For control purpose, verapamil (A2780V) or fumitremorgin C inhibition (A2780) was performed, and drug transporters were stained with APC-conjugated monoclonal antibodies. Both DCG and DCO are able to detect ABCB1-positive SP cells, whereas neither dye can identify SP cells that express ABCG2. Note the extreme separation of ABCB1-SP cells, which made it impossible to measure the fluorescence linearly.
- Conjugate
- Yellow dye